scispace - formally typeset
U

Usama A Sharaf El Din

Researcher at Cairo University

Publications -  32
Citations -  1015

Usama A Sharaf El Din is an academic researcher from Cairo University. The author has contributed to research in topics: Kidney disease & Renal function. The author has an hindex of 9, co-authored 28 publications receiving 769 citations.

Papers
More filters
Journal ArticleDOI

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

TL;DR: Among all randomly assigned patients with Fabry's disease (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 months did not differ significantly between the migAlastat group and the placebo group.
Journal ArticleDOI

Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review

TL;DR: The association between uric acid (UA) and systemic hypertension (Htn), dyslipidemia, glucose intolerance, overweight, fatty liver, renal disease and cardiovascular disease (CVD) on the other side is well recognized as discussed by the authors.
Journal ArticleDOI

Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients

TL;DR: In haemodialysis patients, F GF-23 and ACI were significantly increased, and FGF-23 was independently associated with aortic calcification.
Journal ArticleDOI

The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers.

TL;DR: F GF-23 is strongly correlated to various markers of inflammation and oxidative stress in hemodialysis patients and the association between FGF-23 and vascular calcification was mitigated when corrected for inflammation markers.
Journal ArticleDOI

Diabetic nephropathy: Time to withhold development and progression - A review

TL;DR: In this article, the authors highlight the recent advances in understanding the pathogenesis, diagnosis, the established and the potential renoprotective therapeutic agents that would prevent the development or the progression of diabetic nephropathy.